Healthcare
Thursday, September 22, 2016
BRIEF-Egalet announces results after study of ARYMO ER extended-release tablets
* Announces results from a category 3 oral human abuse
potential study and a category 3 intranasal hap study of product
candidate ARYMO ER extended-release tablets
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment